Document and Entity Information |
Jun. 26, 2025 |
---|---|
Cover [Abstract] | |
Security Exchange Name | NASDAQ |
Amendment Flag | true |
Entity Central Index Key | 0001764974 |
Document Type | 8-K/A |
Document Period End Date | Jun. 26, 2025 |
Entity Registrant Name | Turnstone Biologics Corp. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-41747 |
Entity Tax Identification Number | 82-2909368 |
Entity Address, Address Line One | 9310 Athena Circle |
Entity Address, Address Line Two | Suite 3000 |
Entity Address, City or Town | La Jolla |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92037 |
City Area Code | (347) |
Local Phone Number | 897-5988 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, ($0.001 par value) |
Trading Symbol | TSBX |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Amendment Description | Turnstone Biologics Corp. (the “Company”) is filing this Amendment No. 1 to its Current Report on Form 8-K (the “Amendment”) originally filed with the Securities and Exchange Commission (the “SEC”) on June 27, 2025 (the “Original Form 8-K”), solely to refile a corrected Exhibit 2.1 (Agreement and Plan of Merger, dated June 26, 2025 (the “Merger Agreement”)) to the Original Form 8-K. The copy of the Merger Agreement filed as Exhibit 2.1 to the Original Form 8-K inadvertently omitted the form of CVR Agreement and the form of Support Agreement (each as defined in the Merger Agreement) as Exhibit C and Exhibit D to the Merger Agreement, respectively. The corrected version of the Merger Agreement is filed as Exhibit 2.1 hereto and supersedes and replaces in its entirety Exhibit 2.1 to the Original Form 8-K. Except as stated in this Explanatory Note, this Amendment does not otherwise change or update the disclosure set forth in the Original Form 8-K. |